Human DSG2/CDHF5/HDGC ORF/cDNA clone-Adeno-associate virus(AAV) particle (NM_001943.5)

Cat. No.: vGMAAV001955

Pre-made Human DSG2/CDHF5/HDGC Adeno-associated virus particle for DSG2 in-vivo study, mechanism of action (MOA) research and DSG2-associated gene therapy development.

At GM Vector Core (GMVC), we stand at the forefront of custom AAV development and produce distinct grades of AAVs employing state-of-the-art methodologies. Uncover more about our expertise.

Target products collection

Go to DSG2/CDHF5 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name AAV serotype AAV Grade AAV quantity
vGMAAV001955 Human DSG2 Adeno-associate virus(AAV) particle AAV1, AAV2, AAV2 variant (Y444F), AAV2 variant (Y272F, Y444F, Y500F, Y730F), AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F), AAV2 variant(AAV2.7m8), AAV5, AAV6, AAV8, AAV8-1m, AAV8-2m, AAV8 variant (Y733F, Y447F, Y275), AAV9, AAV-Rh.10, AAV-DJ, AAV-DJ/8, AAV-Retro (Retrograde), AAV9-PHP.B, AAV9-PHP.eB, AAV9-PHP.S, AAV-BR1, AAV-2i8, AAV-SIG, AAV-VEC, AAV4, AAV6.2, AAV6.2FF Pilot Grade 1.0E+12VG/ml
5.0E+12VG/ml
1E+13VG/ml
5E+13VG/ml
1E+14VG/ml
Research Grade 1.0E+12VG/ml
5.0E+12VG/ml
1E+13VG/ml
5E+13VG/ml
1E+14VG/ml
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMAAV001955
Gene Name DSG2
Accession Number NM_001943.5
Gene ID 1829
Species Human
Product Type Adeno-associate virus(AAV) particle (overexpression)
Insert Length 3357 bp
Gene Alias CDHF5,HDGC
Fluorescent Reporter Null
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter CTNT
Resistance Amplicin
ORF Nucleotide Sequence ATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCTTCTCCTGATCTGCTTTAACGTTGGAAGTGGACTTCACTTACAGGTCTTAAGCACAAGAAATGAAAATAAGCTGCTTCCTAAACATCCTCATTTAGTGCGGCAAAAGCGCGCCTGGATCACCGCCCCCGTGGCTCTTCGGGAGGGAGAGGATCTGTCCAAGAAGAATCCAATTGCCAAGATACATTCTGATCTTGCAGAAGAAAGAGGACTCAAAATTACTTACAAATACACTGGAAAAGGGATTACAGAGCCACCTTTTGGTATATTTGTCTTTAACAAAGATACTGGAGAACTGAATGTTACCAGCATTCTTGATCGAGAAGAAACACCATTTTTTCTGCTAACAGGTTACGCTTTGGATGCAAGAGGAAACAATGTAGAGAAACCCTTAGAGCTACGCATTAAGGTTCTTGATATCAATGACAACGAACCAGTGTTCACACAGGATGTCTTTGTTGGGTCTGTTGAAGAGTTGAGTGCAGCACATACTCTTGTGATGAAAATCAATGCAACAGATGCAGATGAGCCCAATACCCTGAATTCGAAAATTTCCTATAGAATCGTATCTCTGGAGCCTGCTTATCCTCCAGTGTTCTACCTAAATAAAGATACAGGAGAGATTTATACAACCAGTGTTACCTTGGACAGAGAGGAACACAGCAGCTACACTTTGACAGTAGAAGCAAGAGATGGCAATGGAGAAGTTACAGACAAACCTGTAAAACAAGCTCAAGTTCAGATTCGTATTTTGGATGTCAATGACAATATACCTGTAGTAGAAAATAAAGTGCTTGAAGGGATGGTTGAAGAAAATCAAGTCAACGTAGAAGTTACGCGCATAAAAGTGTTCGATGCAGATGAAATAGGTTCTGATAATTGGCTGGCAAATTTTACATTTGCATCAGGAAATGAAGGAGGTTATTTCCACATAGAAACAGATGCTCAAACTAACGAAGGAATTGTGACCCTTATTAAGGAAGTAGATTATGAAGAAATGAAGAATCTTGACTTCAGTGTTATTGTCGCTAATAAAGCAGCTTTTCACAAGTCGATTAGGAGTAAATACAAGCCTACACCCATTCCCATCAAGGTCAAAGTGAAAAATGTGAAAGAAGGCATTCATTTTAAAAGCAGCGTCATCTCAATTTATGTTAGCGAGAGCATGGATAGATCAAGCAAAGGCCAAATAATTGGAAATTTTCAAGCTTTTGATGAGGACACTGGACTACCAGCCCATGCAAGATATGTAAAATTAGAAGATAGAGATAATTGGATCTCTGTGGATTCTGTCACATCTGAAATTAAACTTGCAAAACTTCCTGATTTTGAATCTAGATATGTTCAAAATGGCACATACACTGTAAAGATTGTGGCCATATCAGAAGATTATCCTAGAAAAACCATCACTGGCACAGTCCTTATCAATGTTGAAGACATCAACGACAACTGTCCCACACTGATAGAGCCTGTGCAGACAATCTGTCACGATGCAGAGTATGTGAATGTTACTGCAGAGGACCTGGATGGACACCCAAACAGTGGCCCTTTCAGTTTCTCCGTCATTGACAAACCACCTGGCATGGCAGAAAAATGGAAAATAGCACGCCAAGAAAGTACCAGTGTGCTGCTGCAACAAAGTGAGAAAAAGCTTGGGAGAAGTGAAATTCAGTTCCTGATTTCAGACAATCAGGGTTTTAGTTGTCCTGAAAAGCAGGTCCTTACACTCACAGTTTGTGAGTGTCTGCATGGCAGCGGCTGCAGGGAAGCACAGCATGACTCCTATGTGGGCCTGGGACCCGCAGCAATTGCGCTCATGATTTTGGCCTTTCTGCTCCTGCTATTGGTACCACTTTTACTGCTGATGTGCCATTGCGGAAAGGGCGCCAAAGGCTTTACCCCCATACCTGGCACCATAGAGATGCTGCATCCTTGGAATAATGAAGGAGCACCACCTGAAGACAAGGTGGTGCCATCATTTCTGCCAGTGGATCAAGGGGGCAGTCTAGTAGGAAGAAATGGAGTAGGAGGTATGGCCAAGGAAGCCACGATGAAAGGAAGTAGCTCTGCTTCCATTGTCAAAGGGCAACATGAGATGTCCGAGATGGATGGAAGGTGGGAAGAACACAGAAGCCTGCTTTCTGGTAGAGCTACCCAGTTTACAGGGGCCACAGGCGCTATCATGACCACTGAAACCACGAAGACCGCAAGGGCCACAGGGGCTTCCAGAGACATGGCCGGAGCTCAGGCAGCTGCTGTTGCACTGAACGAAGAATTCTTAAGAAATTATTTCACTGATAAAGCGGCCTCTTACACTGAGGAAGATGAAAATCACACAGCCAAAGATTGCCTTCTGGTTTATTCTCAGGAAGAAACTGAATCGCTGAATGCTTCTATTGGTTGTTGCAGTTTTATTGAAGGAGAGCTAGATGACCGCTTCTTAGATGATTTGGGACTTAAATTCAAGACACTAGCTGAAGTTTGCCTGGGTCAAAAAATAGATATAAATAAGGAAATTGAGCAGAGACAAAAACCTGCCACAGAAACAAGTATGAACACAGCTTCACATTCACTCTGTGAGCAAACTATGGTTAATTCAGAGAATACCTACTCCTCTGGCAGTAGCTTCCCAGTTCCAAAATCTTTGCAAGAAGCCAATGCAGAGAAAGTAACTCAGGAAATAGTCACTGAAAGATCTGTGTCTTCTAGGCAGGCGCAAAAGGTAGCTACACCTCTTCCTGACCCAATGGCTTCTAGAAATGTGATAGCAACAGAAACTTCCTATGTCACAGGGTCCACTATGCCACCAACCACTGTGATCCTGGGTCCTAGCCAGCCACAGAGCCTTATTGTGACAGAGAGGGTGTATGCTCCAGCTTCTACCTTGGTAGATCAGCCTTATGCTAATGAAGGTACAGTTGTGGTCACTGAAAGAGTAATACAGCCTCATGGGGGTGGATCGAATCCTCTGGAAGGCACTCAGCATCTTCAAGATGTACCTTACGTCATGGTGAGGGAAAGAGAGAGCTTCCTTGCCCCCAGCTCAGGTGTGCAGCCTACTCTGGCCATGCCTAATATAGCAGTAGGACAGAATGTGACAGTGACAGAAAGAGTTCTAGCACCTGCTTCCACTCTGCAATCCAGTTACCAGATTCCCACTGAAAATTCTATGACGGCTAGGAACACCACGGTGTCTGGAGCTGGAGTCCCTGGCCCTCTGCCAGATTTTGGTTTAGAGGAATCTGGTCATTCTAATTCTACCATAACCACATCTTCCACCAGAGTTACCAAGCATAGCACTGTACAGCATTCTTACTCCTAA
ORF Protein Sequence MARSPGRAYALLLLLICFNVGSGLHLQVLSTRNENKLLPKHPHLVRQKRAWITAPVALREGEDLSKKNPIAKIHSDLAEERGLKITYKYTGKGITEPPFGIFVFNKDTGELNVTSILDREETPFFLLTGYALDARGNNVEKPLELRIKVLDINDNEPVFTQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYRIVSLEPAYPPVFYLNKDTGEIYTTSVTLDREEHSSYTLTVEARDGNGEVTDKPVKQAQVQIRILDVNDNIPVVENKVLEGMVEENQVNVEVTRIKVFDADEIGSDNWLANFTFASGNEGGYFHIETDAQTNEGIVTLIKEVDYEEMKNLDFSVIVANKAAFHKSIRSKYKPTPIPIKVKVKNVKEGIHFKSSVISIYVSESMDRSSKGQIIGNFQAFDEDTGLPAHARYVKLEDRDNWISVDSVTSEIKLAKLPDFESRYVQNGTYTVKIVAISEDYPRKTITGTVLINVEDINDNCPTLIEPVQTICHDAEYVNVTAEDLDGHPNSGPFSFSVIDKPPGMAEKWKIARQESTSVLLQQSEKKLGRSEIQFLISDNQGFSCPEKQVLTLTVCECLHGSGCREAQHDSYVGLGPAAIALMILAFLLLLLVPLLLLMCHCGKGAKGFTPIPGTIEMLHPWNNEGAPPEDKVVPSFLPVDQGGSLVGRNGVGGMAKEATMKGSSSASIVKGQHEMSEMDGRWEEHRSLLSGRATQFTGATGAIMTTETTKTARATGASRDMAGAQAAAVALNEEFLRNYFTDKAASYTEEDENHTAKDCLLVYSQEETESLNASIGCCSFIEGELDDRFLDDLGLKFKTLAEVCLGQKIDINKEIEQRQKPATETSMNTASHSLCEQTMVNSENTYSSGSSFPVPKSLQEANAEKVTQEIVTERSVSSRQAQKVATPLPDPMASRNVIATETSYVTGSTMPPTTVILGPSQPQSLIVTERVYAPASTLVDQPYANEGTVVVTERVIQPHGGGSNPLEGTQHLQDVPYVMVRERESFLAPSSGVQPTLAMPNIAVGQNVTVTERVLAPASTLQSSYQIPTENSMTARNTTVSGAGVPGPLPDFGLEESGHSNSTITTSSTRVTKHSTVQHSYS

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP0379-Ab Anti-DSG2/ CDHF5/ HDGC monoclonal antibody
    Target Antigen GM-Tg-g-MP0379-Ag DSG2 VLP (virus-like particle)
    ORF Viral Vector pGMAD001272 Human DSG2 Adenovirus plasmid
    ORF Viral Vector pGMAAV001325 Human DSG2 Adeno-associate virus(AAV) plasmid
    ORF Viral Vector pGMAAV001955 Human DSG2 Adeno-associate virus(AAV) plasmid
    ORF Viral Vector vGMAD001272 Human DSG2 Adenovirus particle
    ORF Viral Vector vGMAAV001325 Human DSG2 Adeno-associate virus(AAV) particle
    ORF Viral Vector vGMAAV001955 Human DSG2 Adeno-associate virus(AAV) particle


    Target information

    Target ID GM-MP0379
    Target Name DSG2
    Gene Group Identifier
    （Target Gene ID in Homo species)         		1829
    Gene ID 100066038 (Equus caballus), 101088118 (Felis catus), 13511 (Mus musculus), 1829 (Homo sapiens)
    307562 (Rattus norvegicus), 490500 (Canis lupus familiaris), 508151 (Bos taurus), 705805 (Macaca mulatta)
    Gene Symbols & Synonyms DSG2,Dsg2,D18Ertd293e,HDGC,CDHF5
    Target Alternative Names CDHF5,Cadherin family member 5,D18Ertd293e,DSG2,Desmoglein-2,Dsg2,HDGC
    Uniprot Accession O55111,Q14126
    Additional SwissProt Accessions: O55111,Q14126
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category
    Disease Prostate Cancer, Heart failure, Mucocutaneous lymph node syndrome [Kawasaki]
    Disease from KEGG Arrhythmogenic right ventricular cardiomyopathy
    Gene Ensembl ENSECAG00000013616, ENSMUSG00000044393, ENSG00000046604, ENSCAFG00845010678, ENSBTAG00000021923, ENSMMUG00000021095
    Target Classification


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.